Regeneron ($REGN) has resolved concerns raised by a heritage group about traffic that will be generated by its new drug plant in Limerick, Ireland, the Limerick Leader reports. The Tarrytown, NY-based company now can proceed with its €220 million ($303 million) plans to revamp a former Dell plant there for production of drugs currently in the Eylea maker's pipeline. The drugmaker is working out sustainable transportation solutions to minimize car use for the 300 workers it expects to hire. Story | More